159 related articles for article (PubMed ID: 21165379)
1. Health care costs associated with hepatitis C: a longitudinal cohort study.
Krajden M; Kuo M; Zagorski B; Alvarez M; Yu A; Krahn M
Can J Gastroenterol; 2010 Dec; 24(12):717-26. PubMed ID: 21165379
[TBL] [Abstract][Full Text] [Related]
2. Economic burden associated with patients diagnosed with hepatitis C.
McCombs JS; Yuan Y; Shin J; Saab S
Clin Ther; 2011 Sep; 33(9):1268-80. PubMed ID: 21840056
[TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of testing for hepatitis C in former injecting drug users.
Castelnuovo E; Thompson-Coon J; Pitt M; Cramp M; Siebert U; Price A; Stein K
Health Technol Assess; 2006 Sep; 10(32):iii-iv, ix-xii, 1-93. PubMed ID: 16948891
[TBL] [Abstract][Full Text] [Related]
4. Health care costs associated with hepatitis C virus infection in First Nations populations in Ontario: a retrospective matched cohort study.
Mendlowitz A; Bremner KE; Walker JD; Wong WWL; Feld JJ; Sander B; Jones L; Isaranuwatchai W; Krahn M
CMAJ Open; 2021; 9(3):E897-E906. PubMed ID: 34584004
[TBL] [Abstract][Full Text] [Related]
5. Estimating direct healthcare costs attributable to laboratory-confirmed Lyme disease in Ontario, Canada: A population-based matched cohort study using health administrative data.
Shing E; Wang J; Khoo E; Evans GA; Moore S; Nelder MP; Patel SN; Russell C; Sider D; Sander B
Zoonoses Public Health; 2019 Jun; 66(4):428-435. PubMed ID: 30665259
[TBL] [Abstract][Full Text] [Related]
6. The Population Level Cascade of Care for Hepatitis C in British Columbia, Canada: The BC Hepatitis Testers Cohort (BC-HTC).
Janjua NZ; Kuo M; Yu A; Alvarez M; Wong S; Cook D; Wong J; Grebely J; Butt ZA; Samji H; Ramji A; Tyndall M; Krajden M
EBioMedicine; 2016 Oct; 12():189-195. PubMed ID: 27596150
[TBL] [Abstract][Full Text] [Related]
7. Twin epidemics of new and prevalent hepatitis C infections in Canada: BC Hepatitis Testers Cohort.
Janjua NZ; Yu A; Kuo M; Alvarez M; Cook D; Wong J; Tyndall MW; Krajden M
BMC Infect Dis; 2016 Jul; 16():334. PubMed ID: 27436414
[TBL] [Abstract][Full Text] [Related]
8. Health care costs associated with chronic hepatitis C virus infection in Ontario, Canada: a retrospective cohort study.
Wong WWL; Haines A; Bremner KE; Yao Z; Calzavara A; Mitsakakis N; Kwong JC; Sander B; Thein HH; Krahn MD
CMAJ Open; 2021; 9(1):E167-E174. PubMed ID: 33688024
[TBL] [Abstract][Full Text] [Related]
9. Burden of illness of hepatitis C from a managed care organization perspective.
Armstrong EP; Charland SL
Curr Med Res Opin; 2004 May; 20(5):671-9. PubMed ID: 15140332
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population.
Salomon JA; Weinstein MC; Hammitt JK; Goldie SJ
JAMA; 2003 Jul; 290(2):228-37. PubMed ID: 12851278
[TBL] [Abstract][Full Text] [Related]
11. The costs of not treating hepatitis C virus infection in injecting drug users in New Zealand.
Sheerin IG; Green FT; Sellman JD
Drug Alcohol Rev; 2003 Jun; 22(2):159-67. PubMed ID: 12850902
[TBL] [Abstract][Full Text] [Related]
12. Incidence, risk factors, and prevention of hepatitis C reinfection: a population-based cohort study.
Islam N; Krajden M; Shoveller J; Gustafson P; Gilbert M; Buxton JA; Wong J; Tyndall MW; Janjua NZ;
Lancet Gastroenterol Hepatol; 2017 Mar; 2(3):200-210. PubMed ID: 28404135
[TBL] [Abstract][Full Text] [Related]
13. Hepatitis C Cure Is Associated with Decreased Healthcare Costs in Cirrhotics in Retrospective Veterans Affairs Cohort.
Maier MM; Zhou XH; Chapko M; Leipertz SL; Wang X; Beste LA
Dig Dis Sci; 2018 Jun; 63(6):1454-1462. PubMed ID: 29453610
[TBL] [Abstract][Full Text] [Related]
14. Assessing the burden of illness of chronic hepatitis C and impact of direct-acting antiviral use on healthcare costs in Medicaid.
Roebuck MC; Liberman JN
Am J Manag Care; 2019 Jun; 25(8 Suppl):S131-S139. PubMed ID: 31211526
[TBL] [Abstract][Full Text] [Related]
15. Economic burden of epilepsy in children: A population-based matched cohort study in Canada.
Widjaja E; Guttmann A; Tomlinson G; Snead OC; Sander B
Epilepsia; 2021 Jan; 62(1):152-162. PubMed ID: 33258123
[TBL] [Abstract][Full Text] [Related]
16. The burden of hepatitis C virus infection is growing: a Canadian population-based study of hospitalizations from 1994 to 2004.
Myers RP; Liu M; Shaheen AA
Can J Gastroenterol; 2008 Apr; 22(4):381-7. PubMed ID: 18414713
[TBL] [Abstract][Full Text] [Related]
17. Estimating the impact of hepatitis C virus therapy on future liver-related morbidity, mortality and costs related to chronic hepatitis C.
Buti M; San Miguel R; Brosa M; Cabasés JM; Medina M; Angel Casado M; Fosbrook L; Esteban R
J Hepatol; 2005 May; 42(5):639-45. PubMed ID: 15826711
[TBL] [Abstract][Full Text] [Related]
18. What is killing people with hepatitis C virus infection? Analysis of a population-based cohort in Canada.
Krajden M; Cook DA; Wong S; Yu A; Butt ZA; Rossi C; Darvishian M; Alvarez M; Buxton JA; Tyndall M; Janjua NZ
Int J Drug Policy; 2019 Oct; 72():114-122. PubMed ID: 31229445
[TBL] [Abstract][Full Text] [Related]
19. The impact of HCV co-infection status on healthcare-related utilization among people living with HIV in British Columbia, Canada: a retrospective cohort study.
Ma H; Villalobos CF; St-Jean M; Eyawo O; Lavergne MR; Ti L; Hull MW; Yip B; Wu L; Hogg RS; Barrios R; Shoveller JA; Montaner JSG; Lima VD
BMC Health Serv Res; 2018 May; 18(1):319. PubMed ID: 29720155
[TBL] [Abstract][Full Text] [Related]
20. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
